NOTE: This is stability data administration data regarding these concentrations are not available.ĪSHP Recommended Standard Concentrations for Adult Continuous Infusions: 4 mcg/mL.ĪSHP Recommended Standard Concentrations for Pediatric Continuous Infusions: 4 mcg/mL. Only experienced clinicians, skilled in the management of patients in the intensive care or operating room setting, should administer or supervise the use of dexmedetomidine.ĭexmedetomidine has the potential to adhere to some types of natural rubber it is advisable to use administration components made with synthetic or coated natural rubber gaskets.ĭexmedetomidine is compatible with 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Lactated Ringer's Injection, 20% mannitol, 0.3% potassium chloride solution, and 100 mg/mL magnesium sulfate solution.ĭilute the 200 mcg/2 mL (100 mcg/mL) vial with 48 mL of 0.9% Sodium Chloride Injection to provide a final concentration of 4 mcg/mL.ĭexmedetomidine diluted to a final concentration of 8, 12, and 20 mcg/mL with 0.9% Sodium Chloride Injection is stable for up to 48 hours, despite a slight decrease in solution pH seen with increasing concentrations. The patient should not perform activities requiring mental alertness, such as operating a motor vehicle or operating hazardous machinery, for at least 8 hours after taking the film. Vital signs, including orthostatic measurements, should be assessed before administration of any additional doses.ĭue to the risk of hypotension, additional doses are not recommended for patients with systolic blood pressure less than 90 mmHg, diastolic blood pressure less than 60 mmHg, heart rate less than 60 beats per minute, or a postural change in systolic blood pressure of 20 mmHg or more or a change in diastolic blood pressure of 10 mmHg or more. For partial doses, prepare as stated above. If agitation persists after the initial dose, an additional 2 doses may be administered at least 2 hours apart. During clinical studies, maximum reductions in heart rate and blood pressure usually occurred 2 hours after a dose. Ensure that patient is alert and not experiencing orthostatic or symptomatic hypotension prior to resuming ambulation. Instruct the patient not to chew or swallow the film.Īfter administration, the patient should remain seated or lying down. Instruct the patient to close their mouth and allow the film to dissolve. Instruct patient to avoid food or drink for at least 15 minutes after sublingual administration.įor buccal administration, instruct the patient to place the film on the inside of the lower lip and to avoid food or drink for at least 1 hour after buccal administration. Give the pouch to the patient and instruct them to remove the film with clean, dry hands.įor sublingual administration, instruct the patient to place the film under the tongue, close to the base of the tongue on either the left or right side. If administering the full dose, skip this step. Discard unused half in waste container and place the patient's dose back in the pouch. Cut the film in half between the dots on the film with clean, dry scissors. If administering a partial dose, remove the film from the pouch with clean, dry hands. Open the sealed pouch by tearing at the notch and across the pouch. The medication should be given immediately after the pouch is opened and dose prepared. Keep the film in the foil package until ready to administer. Only administer under supervision of a health care provider the patient's vitals and mental status alertness should be assessed after administration to avoid falls and syncope.įor sublingual or buccal administration only.
0 Comments
Leave a Reply. |